

Insert Research / PIC Site Hospital Address

DEPARTMENT OF GASTROENTEROLOGY

Insert PI or local collaborator contact details

Date typed: Date as postmark

Our ref: TA/TH

Dear Doctor

Predicting 5-aminosalicylate induced nephrotoxicity in patients with inflammatory bowel disease.

I am writing on behalf of the British Society of Gastroenterology, the Renal Association and the UK IBD Genetics Consortium to ask for your help in identifying patients for this study (NIHR CRN 9862).

Nephrotoxicity is a serious but rare idiosyncratic complication of 5-ASA therapy. A 2001/2 postal survey of BSG and RA members suggested an incidence of 5-ASA induced nephrotoxicity of approximately one in 4000 patients / year. Whilst the incidence is low, the morbidity and costs to the health economy are high with a proportion of patients developing end stage renal failure.

Recent studies employing genome wide association technology have successfully elucidated a genetic contribution for a number of different adverse drug reactions. For some reactions, for example abacivir hypersensitivity, it is now clear that a single gene locus can provide adequate predictive accuracy to allow a genetic test to be used in clinical settings. In this study we will use the same methodology to identify clinically useful genetic markers that predict 5-ASA induced nephrotoxicity so that these drugs can be avoided, or renal monitoring intensified, in genetically high risk patients. The first cohort of 100 patients will be recruited from the UK and then a replication cohort will be recruited internationally.

We would be grateful if you would consider offering your institution as a research or patient identification site for this project. We anticipate that each UK hospital might be looking after 3-4 patients who meet the inclusion criteria. These might include patients previously submitted to the 2001/2 postal survey, as well as any patients who have developed this complication more recently.

Screening questions for study inclusion:

- Current age > 16 years
- Normal Creatinine or eGFR at baseline
- ≥50% rise in serum creatinine (with corresponding fall in eGFR, anytime after introduction of 5-ASA)
- Medical opinion implicating 5-ASA justifies drug withdrawal, even if temporary

I enclose a copy of the patient information sheet. If you would like to get involved or would like any further information then please do not hesitate to contact me or visit www.ibdresearch.co.uk.

With best wishes

Yours sincerely

Insert name of PI